One-year follow-up of disease burden and medication changes in patients with myasthenia gravis: From the MG Patient Registry.

In both groups, but more so in the high-burden group, patients infrequently achieved MSE after 1 year of MG treatment. Baseline low disease burden, improvement at 6 months and no pyridostigmine use were associated with a higher likelihood of MSE at 12 months.